Key facts
- It has raised $1.4M; the latest was Early Stage VC in Dec 2025.
- Notable investors include Cowin Capital, Entropy Capital, Hunan Shangyi Guanxi Asset Management Company Limited, Shenzhen Lihe Science and Technology Innovation.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Aidi Beike Biopharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Aidi Beike Biopharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aidi Beike Biopharmaceutical
Developer of genetic medicine designed for virus removal. The company focuses on the research and development of genetic drug using type I CRISPR technology, providing advanced the genetic medicine solution for patients.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2023
- Website
- edibeck.cn/
- Ownership
- Privately Held (backing)
Aidi Beike Biopharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aidi Beike Biopharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aidi Beike Biopharmaceutical in its N-PORT filings yet. We sweep new filings monthly.